Cambridge University spin-out, Morphogen-IX, is developing bone morphogenetic proteins (BMPs) to treat pulmonary arterial hypertension (PAH).
It raised $23.2 million Series B financing in December 2018. The Series B was led by Medicxi, alongside investments from Cambridge Innovation Capital and Cambridge Enterprise.
The investment will support formal preclinical development of its lead candidate, MGX292, and initiation of clinical trials by 2021. MGX292 is a protein-engineered variant of BMP9 that has proven highly efficacious and safe in extensive preclinical studies. MGX292 is the first agent with the potential to be truly disease-modifying and to transform the lives of patients with PAH.
The science behind Morphogen-IX is based on years of research in the British Heart Foundation funded laboratory of Professor Nick Morrell and colleagues at the University of Cambridge. The company employs a semi-virtual model with a hub based on the Babraham Research Campus. David Grainger is chairman of the Morphogen-IX board.